• English
  • Sign In
  • Contact Us
Webinars » Rapid Identification of Diverse High-Affinity SARS-CoV-2 Antibodies

Rapid Identification of Diverse High-Affinity SARS-CoV-2 Antibodies

The SARS-CoV-2 pandemic necessitated the rapid development of high-quality monoclonal antibodies (mAbs) for therapeutic, diagnostic and vaccine development. By harnessing cutting-edge single B cell screening technology and capitalizing on the rabbit's unique ability to generate antibodies of high specificity and affinity, we show how GenScript isolated, screened and characterized a diverse range of high-affinity rabbit mAbs towards the Spike/RBD protein in under 24 hours. We will also share how these antibodies can be further improved for their affinities through our synthetic mutant libraries.

You will learn:

  • We will review different antibody generation methods
  • We will detail how single B cell screening greatly accelerates the discovery of diverse high affinity SARS-CoV-2 Spike/RBD mAbs
  • We will highlight how antibody affinity can be further optimized for your research application using synthetic mutant libraries

  • Speaker:
    Grace Tan, Ph.D. Product Manager, GenScript Reagent Antibody Services
    Maung Nyan Win, Ph.D. Senior Field Application Scientist, GenScript
  • Date: Sept 30th, 2020
  • Time: 1 PM EST │10 AM PST
  • Time:

Speaker Bio

Grace Tan, Ph.D. is the Product Manager of Reagent Antibody Services at GenScript. She graduated with her Ph.D. in Pharmacology from Stony Brook University where she structurally characterized novel inhibitors of insulin degrading enzyme and also worked on developing a new approach to determine the substrate spectrum of an ubiquitin conjugating enzyme.

Maung Nyan Win, Ph.D, is a Senior Field Application Scientist at GenScript. He did his undergraduate studies in Chemical Engineering at Virginia Commonwealth University and received his doctoral degree in Chemistry from California Institute of Technology with research emphasis in Synthetic Biology. He then did his postdoctoral research in metabolic engineering at Stanford University. Before joining GenScript, he was a senior research scientist at three different companies in both biotech and biopharmaceutical industries.